Summary
Updated Aug 30, 2026
George Golumbeski is Director of Acumen Pharmaceuticals, Inc. (ABOS). 5 SEC Form 4 filings on record going back to 2025, most recently on 5 June 2026.
Recent Transactions
2Every recent SEC Form 4 transaction George Golumbeski has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies George Golumbeski files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ORBIMED ADVISORS LLC - $5.47M of STTK open-market activity in the last 12 months
- Mona Ashiya - $5.47M of STTK open-market activity in the last 12 months
- Arundathy N. Pandite - $409K of STTK open-market activity in the last 12 months
- Clay B. Siegall - $250K of STTK open-market activity in the last 12 months
- Abhinav A. Shukla - $183K of STTK open-market activity in the last 12 months
- Derek M. Meisner - $105K of ABOS open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is George Golumbeski?
George Golumbeski is a corporate insider, tracked as Director of Acumen Pharmaceuticals, Inc. (ABOS). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has George Golumbeski submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of George Golumbeski's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow George Golumbeski and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
